51 results about "Large cell lung cancer" patented technology

A method of treating large cell lung cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof, thereby treating the large cell lung cancer in the subject.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

The invention discloses a marine bacillus polypeptide and a preparation and an application thereof and belongs to the technical field of marine microorganism medicines. The marine bacillus polypeptide is from metabolites of antarctic marine bacillus N11-8 subjected to fermentation cultivation; 15 amino acid sequences at N-ends of the active polypeptide are ASTGSQKVTVYAVAD; the active polypeptide has relatively high cytotoxicity to a plurality of tumor cells such as human hepatoma carcinoma cell BEL-7402, human ovarian carcinoma cells NIH:OVCAR-3, human renal clear cell carcinoma cells 786-0 and human large cell lung cancer cells NCI-H460, and has relatively good research and application value. The polypeptide can be applied to medicines for preventing and / or treating the cancers.

The invention belongs to the technical field of medicines and relates to a benzothiazole formamide compound and application thereof. The benzothiazole formamide compound comprises a derivative of the benzothiazole formamide compound and pharmaceutically applicable salt; a general molecular formula is shown in the description, wherein R1, R2 and Ar are described as claims and the description. The benzothiazole formamide compound and addition salt of the pharmaceutically applicable acid of the compound can be combined with an existing medicine or can be independently utilized as an epidermal growth factor tyrosine kinase inhibitor for treating related diseases of epidermal growth factor acceptor signal transduction disorder, such as small cell lung cancer, squamous cancer, glandular cancer, large cell lung cancer, colorectal cancer, breast cancer, ovarian cancer and renal cell carcinoma. A formula is shown in the description.

The invention provides a method for preparing bile and patchouli rhinitis tablets. The rhinitis tablets are prepared from 15g of porcine bile paste, 560g of patchouli, 560g of dahurian angelica, 450g of cocklebur fruit, 375g of centipeda, 250g of schizonepeta, 250g of honeysuckle, 250g of wild chrysanthemum and 1.5g of menthol serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the cocklebur fruit content is greatly improved. The invention also provides application of the bile and patchouli rhinitis tablets in preparation of a medicament for inhibiting propagation of human large cell lung cancer NC1-H460 cells.

The invention discloses a (2-pyridylaldehyde)-2,6 pyridine diacylhydrazone copper compound and a preparation method.The copper compound has high anti-cancer activity and can be used as the raw material for preparing medicine for treating human breast cancer cells (MDA) and Human large cell lung cancer (NCI-H460).Compared with platinum anti-cancer medicine commonly used at present, the copper compound has the advantages of being high in anti-cancer activity, good in lipid solubility, low in cost, simple in preparation method and the like, and provides a new means for anti-cancer medicine development.

The invention belongs to the field of antineoplastic compounds and relates to a water-soluble derivative of diphenylethene compounds, especially a water-soluble derivative of trans-4-[2-(3,5-dimethoxyphenyl)vinyl]-1,2-benzenediol as shown in the formula I, a preparation method and a usage thereof in the preparation of antitumor drugs. The water-soluble derivative of diphenylethene compounds is prepared through water-soluble reconstruction by taking the compound, trans-4-[2-(3,5- dimethoxyphenyl)vinyl]-1,2-benzenediol, as a parent nucleus. Results of in vitro antineoplastic tests show that the water-soluble derivative of diphenylethene compounds has significant effects in inhibiting brain glioma cells SF188 and U87wt, breast cancer cells MCF-7wt and large cell lung cancer cells H460. The activity of the cells decreases along with the increase of drug concentration. The derivative disclosed by the invention is an effective antitumor agent and further, the derivative can be used for preparing the antitumor drugs.

The invention discloses a method for preparing diaporthein B and application of the diaporthein B to the preparation of antitumor medicaments. In the method, the diaporthein B with antitumor activity is separated from a liquid fermentation culture of a marine fungus, namely Eutypella scoparia FS26. The method has the advantages that culture conditions are mild, a culture medium is easy to prepare, fermentation time is short, separation and purification steps are simple, the mass production can be realized under manual control conditions and the like, and the problem of medicament sources can be solved more conveniently. Through the experiment, IC50 values of the diaporthein B for a glioma cell SF-268, a breast cancer cell MCF-7 and a large-cell lung cancer cell NCI-H460 are 92mu M, 44mu M and 9.9mu M respectively, the diaporthein B has remarkable antitumor activity, and IC50 values of a positive control, namely cis-platinum for the three tumor cell strains are 4.6mu M, 4.1mu M and 3.0mu M respectively. Therefore, a candidate compound is provided for researching and developing novel antitumor medicaments, and a scientific evidence is provided for developing and utilizing natural active substances which are derived from marine microorganisms.

The invention relates to the nucleic acid sequences of two novel human ARL-related gene variants (ARLV1 and ARLV2) and the polypeptides encoded by ARLV1 and ARLV2.The invention also relates to the process for producing the polypeptides encoded by ARLV1 and ARLV2.The invention further relates to the use of the nucleic acid of ARLV1 and ARLV2 and the polypeptide encoded by ARLV1 and ARLV2 in diagnosing diseases associated with the deficiency of human ARLV gene, in particular large cell lung cancer or hepatocellular carcinoma.

The invention discloses a bladder cancer cell inhibitor and a preparation method thereof. The complex dichloro.2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline.R, R.platinum cyclohexanediamine (II) has chirality. With 1,10-phenanthroline.5,6.dione and 4.methoxybenzaldehyde as raw materials, 2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline is prepared; potassium chloroplatinite is added to prepare 2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline.dichloro platinum (II); and finally, cyclohexanediamine is added to obtain the product bladder cancer cell inhibitor. The complex has excellent anti-tumor activity and can be applied to the drugs against bladder cancer and human large-cell lung cancer cells.

The invention provides a pharmaceutical application of gallic acid. The gallic acid has a tumor treatment effect, and has an obvious inhibition effect on eight different human tumor cells, namely human liver cancer cells, human lung cancer cells (large cell lung cancer), primary colorectal cancer cells, human cervical squamous carcinoma cells, human gastric cancer cells, human prostate cancer cells, human lung adenocarcinoma cells (pleural effusion) and human colorectal adenocarcinoma cells.

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues,and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide forapplication, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

A method of treating large cell lung cancer in a subject in need thereof is provided. The method comprising administering to the subject a therapeutically effective amount of a peptide comprising an amino acid sequence as set forth in SEQ ID NO:1 or an analog or derivative thereof, thereby treating the large cell lung cancer in the subject.

The invention relates to the nucleic acid sequences of four novel human SMAPK3-related gene variants (SMAPK3V1, SMAPK3V2, SMAPK3V3 and SMAPK3V4) and the polypeptides encoded by SMAPK3V1 and SMAPK3V2. The invention also relates to the process for producing the polypeptides encoded by SMAPK3V1 and SMAPK3V2. The invention further relates to the use of the nucleic acid of SMAPK3V1, SMAPK3V2, SMAPK3V3 and SMAPK3V4 and the polypeptide encoded by SMAPK3V1 and SMAPK3V2 in diagnosing diseases associated with the deficiency of human SMAPK3V gene, in particular large cell lung cancers and Burkitt lymphoma.

The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants. The invention also relates to the process for producing the polypeptides of the variants. The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.

The invention discloses application of a compound helicascolide A to preparation of anti-tumor medicines. The compound helicascolide A has quite strong cytotoxic activity for glioma cells SF-268, breast cancer cells MCF-7, large-cell lung cancer cells NCI-H460 and human liver cancer cells HepG-2. It is shown that the compound helicascolide A has good anti-tumor activity, and can be applied to preparation of the anti-tumor medicines. Thus, candidate medicines are provided for the research and development of new anti-tumor medicines, and the scientific basis is provided for the development and utilization of natural active substances from plant endophytic fungi.

The invention relates to the nucleic acid sequences of two novel human ARL-related gene variants (ARLV1 and ARLV2) and the polypeptides encoded by ARLV1 and ARLV2. The invention also relates to the process for producing the polypeptides encoded by ARLV1 and ARLV2. The invention further relates to the use of the nucleic acid of ARLV1 and ARLV2 and the polypeptide encoded by ARLV1 and ARLV2 in diagnosing diseases associated with the deficiency of human ARLV gene, in particular large cell lung cancer or hepatocellular carcinoma.

The invention discloses application of Lycojaponicumin A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments, and belongs to the technical field of new application of medicaments. The Lycojaponicumin A can prominently inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung flat epithelial cancer cells QG-5 cultured in vitro, has a low inhibiting effect on human normal liver cells LO2 and peripheral blood lymphocytes, and shows obvious selectivity. The application of the Lycojaponicumin A in preparation of the medicaments for treating the lung cancer is made public for the first time; and because the skeleton type is completely novel, the Lycojaponicumin A has an unexpectedly strong lung cancer cell inhibiting activity.

The invention relates to a reagent kit for lung cancer detection. The reagent kit comprises a reagent for specific detection of miRNA (micro ribonucleic acid)-6070. The reagent kit can effectively detect a large cell lung cancer and quickly achieve quantitative detection of miRNA, and therefore achieves the purpose of quickly and effectively detecting the large cell lung cancer.

The invention belongs to the field of medicines, and particularly relates to a novel arylurea-containing 4-arylpyran derivative of a structure as shown in a general formula (I) as shown in the specification and application of the novel arylurea-containing 4-arylpyran derivative of the structure as shown in the general formula (I) as shown in the specification. The derivative is as shown in the general formula (I) as shown in the specification, and can be used medicinally when salts are formed by adding acids into the derivative, wherein R and Ar are defined in the specification. Results of pharmacological activity screening of the compound show that the compound has significant inhibiting effects on human colon cancer cells HT-29, human lung adenocarcinoma cell A549 and human large cell lung cancer cells H460, and has good anti-tumor medicine development and application prospects.

The invention discloses application of Chukrasone A in preparation of medicaments for treating lung cancer. The compound shows excellent activity for resisting lung cancer, can be used for preparing medicaments for resisting lung cancer, and belongs to the technical field of novel application of medicaments. Chukrasone A can remarkably inhibit in vitro cultured non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, squamous cell lung carcinoma cells HTB-8 and human lung epidermoid carcinoma QG-5, but hardly has inhibition effects on human normal hepatocytes LO2 and peripheral blood lymphocytes, and shows a remarkable selectivity. The application of Chukrasone A in preparation of medicaments for treating lung caner is disclosed for the first time, and the frame type belongs to a brand-new frame type, so that the inhibition activity of the Chukrasone A to lung cancer cells is unexpectedly strong.

The invention relates to an imidazopyridine mercapto-acetamide derivative shown as a general formula I or a medicinal salt thereof, a pharmaceutical composition containing the compound, and application of the pharmaceutical composition to the preparation of a human solid tumor resistant medicament. Human solid tumors include human large cell lung cancer, human liver cancer, human colon tumor and human breast cancer. The general formula I is shown in the description.

The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants.The invention also relates to the process for producing the polypeptides of the variants.The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.

The invention discloses an application of Houttuynoid A in preparing drugs for treating lung cancer. As a compound, the Houttuynoid A shows high anti-lung cancer activity, can be used for preparing the anti-lung cancer drugs and belongs to the technical field of new uses of the drugs. The Houttuynoid A is capable of remarkably inhibiting non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung epidermoid carcinoma cells QG-5, but is smaller in effect of inhibiting human normal hepatocytes LO2 and peripheral blood lymphocytes, i.e. obvious selectivity is shown. The application of the Houttuynoid A in preparing the drugs for treating the lung cancer is disclosed for the first time. Moreover, the skeleton type of the Houttuynoid A is fire-new, and how strong the inhibitory activity of the Houttuynoid A on the lung cancer cells is unexpected.

The invention discloses an application of Lycojaponicumin C in the preparation of medicines for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for the preparation of anti-lung cancer medicines and belongs to the technical field of new applications of medicines. The Lycojaponicumin C can be used for obviously inhibiting a non-small cell lung cancer cell A549, a large-cell lung cancer cell NCI-H460, a lung squamous carcinoma cell HTB-8 and a human lung epidermoid carcinoma cell QG-5 which are cultured in vitro, has a low inhibition effect on a human normal lung cell LO2 and a peripheral blood lymphocyte and shows up obvious selectivity. The application of the Lycojaponicumin C in the preparation of the medicines for treating the lung cancer is disclosed for the first time. As the skeleton type of the Lycojaponicumin C belongs to a brand-new skeleton type, the Lycojaponicumin C has unexpected strong inhibitory activity on the lung cancer cells.

The invention discloses an application of polyflavanostilbene A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments and belongs to the technical field of new uses of the medicaments. The polyflavanostilbene A can significantly inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous carcinoma cells HTB-8 and human lung squamous cell carcinoma cells QG-5, which are cultured in vitro, realize a smaller inhibition effect against human normal liver cells LO2 and peripheral blood lymphocytes and show obvious selectivity. The use of the polyflavanostilbene A in the preparation of the medicaments for treating the lung cancer, disclosed by the invention, belongs to the first disclosure, the framework type belongs to the brand new framework type, and the strong inhibition activity against the cells of the lung cancer is further unexpected.

The invention discloses application of Linderolide H in the preparation of lung cancer drugs; the compound exhibits good lung cancer resisting activity, is applicable to the preparation of lung cancer drugs and belongs to the technical field of novel applications of drugs. Linderolide H can significantly inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous carcinoma cells HTB-8 and human lung squamous carcinoma cells QG-5 cultured in vitro, but exhibit low inhibitory action on human normal liver cell LO2 and peripheral blood lymphocyte, and shows significant selectivity; the application of Linderolide H in the preparation of lung cancer drugs is disclosed herein for the first time; since a framework is of brand-new type, the inhibitory activity for lung cancer cells is unexpectedly high.

The invention discloses application of Houttuynoid E in preparing a medicine for treating lung cancer. The compound shows high anti-lung cancer activity and can be used for preparing an anti-lung cancer medicine, belonging to the technical field of new application of a medicine. The Houttuynoid E can obviously suppress the non-small cell lung cancer cell A549, large cell lung cancer cell NCI-H460, squamous cell lung cancer cell HTB-8 and human lung squamous epithelium cancer cell QG-5 cultured in vitro while realizing a relatively low effect on suppressing the human normal liver cell LO2 and peripheral blood lymphocyte cell, thereby showing obvious selectivity. The application of Houttuynoid E in preparing a medicine for treating lung cancer is disclosed for the first time; and the skeleton type is a brand new one, and the activity in suppressing lung cancer cells is unexpectedly strong.